This study evaluated the usefulness of PET imaging biomarkers with 64Cu-PCTA-cetuximab and 18F-FDG-PET for anti-EGFR immunotherapy in ESCC models. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.